Vice President, Lifecycle Leader, Daraxonrasib – Lung Cancer at Revolution Medicines

You're a seasoned biopharmaceutical executive with at least 15 years of experience, including leading global oncology NME launches, and possess a Bachelor's deg

Work type: onsite

Location: Redwood City, California, United States

Salary: $294,000 – $367,000/yr

Type: Full-time

Summary

You're a seasoned biopharmaceutical executive with at least 15 years of experience, including leading global oncology NME launches, and possess a Bachelor's degree or higher. **What makes it worth a look...** This full-time, on-site leadership role at Revolution Medicines in Redwood City, California offers a base salary of $294,000 - $367,000 per year, focusing on shaping the global lifecycle strategy for a promising lung cancer therapy. **You might be a good fit if you...** * Have a proven track record of leading global NME launches in oncology. * Possess deep expertise in lifecycle management, brand strategy, global marketing, and market access. * Have experience operating in multifunctional, high-pressure environments with ambitious milestones. * Are comfortable influencing senior stakeholders and developing strategic roadmaps.

Job Description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

Revolution Medicines is seeking a strategic, enterprise-minded Lifecycle Leader to lead the global lifecycle strategy for the daraxonrasib Lung Cancer program. This role is accountable for shaping and executing an integrated end-to-end molecule strategy — from pivotal development through commercialization and post-launch expansion — to maximize long-term patient and enterprise value.

The Lifecycle Leader serves as the cross-functional integrator and strategic architect for daraxonrasib, aligning disease area priorities, development strategy, regulatory considerations, and commercialization planning into a unified global roadmap. This individual will lead the cross-functional Lifecycle Team, drive strategic trade-offs within a portfolio context, and ensure seamless execution across geographies and functions.

The role requires deep commercialization expertise, including demonstrated NME launch leadership in oncology, and the ability to translate scientific progress into differentiated, launch-ready strategies that deliver meaningful impact for patients and sustained value for the organization.

Key Responsibilities

Lifecycle & Commercial Strategy

• Define and continuously refine the global lifecycle strategy for daraxonrasib across indications, lines of therapy, and combination opportunities.

• Identify cross-indication synergies, expansion pathways, and systemic program risks, drive mitigation strategies.

• Translate clinical data, competitive insights, and regulatory strategy into differentiated commercial positioning and value propositions.

• Ensure alignment between disease area strategy and molecule-level priorities.

• Architect and lead the Lifecycle Team (LCT) and working groups in a fit-for-purpose manner.

• Partner closely with Clinical Development, Regulatory, Medical Affairs, Market Access, and Portfolio teams to ensure integrated decision-making.

• Serve as a core member of governance forums, preparing recommendations and driving enterprise alignment.

• Escalate major strategic decisions with clearly articulated recommendations aligned with portfolio principles.

• Develop and own the strategic roadmap, milestones, financial targets, and key objectives of the asset.

• Balance long-term strategic priorities with short-term operational execution.

• Build, lead, and develop a high-performing, highly cross-functional lifecycle team, driving alignment and accountability across team members, senior leaders and functions to execute an integrated global lifecycle strategy.

• Contribute to the maturation and evolution of the Lifecycle function by establishing scalable frameworks, best practices, and operating models that enable integrated, end-to-end asset strategy across the portfolio

• Foster a collaborative, cross-functional culture that embraces innovation, agility, and accountability.

• Serve as a trusted advisor to executive leadership on lifecycle optimization and commercial value creation.

• Bachelor’s degree required, MBA or advanced degree preferred.

• 15+ years of progressive biopharmaceutical experience, with significant oncology commercialization leadership.

• Demonstrated success leading at least one global NME launch in oncology.

• Deep expertise in lifecycle management, brand strategy, global marketing, and market access.

• Proven experience operating in multifunctional, high-pressure environments with ambitious milestones.

• Strong executive presence and ability to influence senior stakeholders.

• Experience in RAS-driven or precision oncology markets.

• Experience expanding assets across multiple lines of therapy and disease area settings.

• Prior experience in a rapidly growing biotechnology company.

• Global launch experience across U.S. and EU markets.

Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.

View this job on nocollar jobs